[3]Mok T, Camidge DR, Gadgeel SM, et.al Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020 Aug;...
integrated efficacy and safety of brigatinib following alectinib treatment in the alta-2 and j-alta studies. 2. ep08.02-009 - progression pattern, resistance mechanism and subsequent therapy for alk positive nsclc in the era of se...
4. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Ann Oncol, 2020, 31(8):1056-1064. 5. Zhou CC, Kim SW, Reungwetwattana...
[4]Leonetti Alessandro, Minari Roberta, Boni Luca, et al. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. Clin Lung Cancer, 2021, 22: 473-477. [5...
7. Horn L, Wang Z, Wu G, et al. Phase 3 Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK)–Positive NSCLC Patients:eXalt3[EB/OL]. WCLC 2020. 8. https://www.pfizer.com/news/press-release/press-release-detail/lorbrenar-lorlatinib-significantly-improves-pro...
中枢神经系统转移的管理策略主要依赖于局部治疗（手术、全脑放射治疗和立体定向放射外科），但可以跨越血脑屏障的小分子全身治疗的出现改善了中枢神经系统受累的NSCLC患者的预后，包括ALK阳性的NSCLC。ALK抑制剂已成为晚期ALK阳性NSCLC的标准治疗选择。第一代ALK抑制剂crizotinib的有效率接近75%，中位无进展生存期（PFS）近...
2024年11月29日,上海市东方医院周彩存教授团队在 Nature Reviews Clinical Oncology 杂志发表了题为“The changing treatment landscape of EGFR-mutant non-small-cell lung cancer”的综述文章,系统论述了EGFR突变NSCLC治疗格局的变化。 对此,“医学界”特邀该文第一作者——上海市东方医院周斐教授,就NSCLC靶向治疗的新...
与克唑替尼相比,未经治疗的ALK阳性晚期NSCLC患者获得了更大的临床益处,具有更高的ORR和潜在的更长的PFS,这一临床获益效果与EML4::ALK变体或ALK突变、TP53突变或旁路耐药改变无关。 SCI 19 August 2023 Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer ...
韩宝惠教授表示,在阿来替尼中国上市后近三年的临床实践中,一线阿来替尼治疗ALK阳性晚期NSCLC不仅有效推迟了患者的肿瘤进展时间,且毒副作用较轻,患者在用药期间依旧可以保障高质量的生活,患者的整体生存时间获益也在ALEX III期研究中得到了印证。2020年5月11日,Annals of Oncology 上在线发表了ALEX研究的最新研究数据。
ALK+=positive for the biomarker called anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer. Important Safety Information & Indications Who is ALECENSA for? ALECENSA is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anapl...